Abel Taylor J, Ryken Timothy, Lesniak Maciej S, Gabikian Patrik
Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Surg Neurol Int. 2013 May 2;4(Suppl 4):S289-93. doi: 10.4103/2152-7806.111305. Print 2013.
With therapies for systemic malignancy improving, life expectancy for cancer patients is becoming increasingly dependent on control of brain metastatic disease. Despite improvements in surgical and radiotherapy modalities for control of brain metastasis, the prognosis for patients with brain metastases is poor. The development of controlled release polymers has lead to novel new therapies for malignant brain tumors consisting of direct surgical delivery of chemotherapy agents to the tumor bed and sustained chemotherapy release over a prolonged period of time. Although there is a large body of literature in support of BCNU polymer wafer for primary brain malignancy and experimental brain metastases, clinical studies evaluating the BCNU polymer wafer for brain metastatic disease are relatively sparse. In this review, we discuss the role of the BCNU polymer wafer for brain metastasis focusing specifically on rationale for use of locally delivered sustained release polymers, history of the BCNU polymer wafer, and emerging studies examining the role of the BCNU polymer wafer for metastatic brain tumors.
随着全身恶性肿瘤治疗方法的不断改进，癌症患者的预期寿命越来越依赖于对脑转移疾病的控制。尽管在控制脑转移的手术和放疗方式上有所改进，但脑转移患者的预后仍然很差。控释聚合物的发展带来了针对恶性脑肿瘤的新型治疗方法，包括将化疗药物直接手术递送至肿瘤床并在较长时间内持续释放化疗药物。尽管有大量文献支持卡莫司汀（BCNU）聚合物薄片用于原发性脑恶性肿瘤和实验性脑转移，但评估BCNU聚合物薄片用于脑转移疾病的临床研究相对较少。在这篇综述中，我们讨论了BCNU聚合物薄片在脑转移中的作用，特别关注局部递送缓释聚合物的使用原理、BCNU聚合物薄片的历史，以及研究BCNU聚合物薄片在转移性脑肿瘤中作用的新兴研究。
